Nanosized Trojan horses created from a patient’s own immune cells have successfully treated inflammation by overcoming the body’s complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.
An international team, led by researchers at Houston Methodist Research Institute, described the creation of nanoparticles called leukosomes and evaluated their ability to treat localized inflammation in the May 23 issue of Nature Materials (early online).
Recent approaches to treating inflammatory diseases have been unsuccessful because an already overactive immune system treats simple nanoparticles as foreign invaders and clears them from the body, preventing them from reaching their target.
“A better approach for building effective drug delivery platforms is to find inspiration for their design in the composition of the immune cells of our body,” said Ennio Tasciotti, Ph.D., director of the Center for Biomimetic Medicine at Houston Methodist Research Institute and the paper’s senior author. “Immune cells such as leukocytes freely circulate in blood vessels, recognize inflammation, and accumulate in inflamed tissues. They do so by using special receptors and ligands on their surface. We purified leukocytes from a patient, then integrated their special ligands and receptors into the leukosome surface. Using the body’s own materials, we built a drug delivery system camouflaged as our own body’s defense system—thus the Trojan horse.”
In its normal form, acute inflammation is a necessary and beneficial part of the body’s defense against infection. However, under certain conditions, inflammation can turn from a friend to a vicious foe, damaging or destroying healthy cells. This is the case for autoimmune disorders such as rheumatoid arthritis, lupus and inflammatory bowel disease, or in illnesses such as Alzheimer’s, cancer, cardiovascular disease and Type 2 diabetes.
Leukosomes are able to target inflamed tissues because they retain the same surface properties of the immune cell membranes from which they are made. To evaluate leukosomes’ effectiveness as drug carriers, Tasciotti and his colleagues created vesicles from mouse leukocytes and filled them with dexamethasone (DXM), an anti-inflammatory agent.
“We used ‘personalized’ DXM-loaded leukosomes to treat inflammation in mice,” Tasciotti said. “After administering the leukosomes, we observed their attachment to the surface of blood vessels surrounding the inflamed tissue, and they selectively delivered DXM to the affected cells.”
The treated mice showed definite signs of improvement, including resolution of the inflammation, a significant reduction in tissue thickness, and a reversal of the immune response that is commonly seen in inflammation.
The success of the team’s initial leukosome trial is encouraging, Tasciotti said, and suggests that membranes purified from any other cell types could also be used as biomimetic nanocarriers to treat other diseases.
“By combining cell biology with nanotechnology, we can create valuable medical tools that work within, and not around, the laws of nature,” he said.
Learn more: Nanoscale trojan horses treat inflammation
The Latest on: Treating inflammation
via Google News
The Latest on: Treating inflammation
- Stress, Inflammation, and Microbes: A Moody Trinityon November 30, 2019 at 8:12 pm
causing a reduction in pro-inflammatory chemicals and conferring resiliency on their new host. This interesting experiment shows that purely psychological stress can make changes to the immune system ...
- Causes and treatment of a split lipon November 29, 2019 at 11:11 pm
Most cases of a split lip are due to cheilitis, which is inflammation of the lips. Using mild home remedies may speed healing in some cases, but a doctor may sometimes need to prescribe stronger ...
- Knee Bursitis Treatment Market 2019 Research and Development- Novartis, Pfizer, Merck, Amgen, Bayer, AVEO Pharmaceuticalson November 29, 2019 at 11:01 pm
operation situation and future development trend of Knee Bursitis Treatment Market on the basis of stating current situation of the industry in 2019. Knee bursitis is inflammation of a small ...
- Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology and Market Forecast-2028on November 29, 2019 at 9:23 am
All the above treatments are aimed at stopping the inflammatory response to prevent further demyelination and secondary axonal injury. Other treatments may be considered in patients with refractory ...
- Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG miceon November 29, 2019 at 2:45 am
We conclude that treating TNF inhibitor alone reduced peripheral arthritis score and spinal inflammation in curdlan-injected SKG mice but did not decrease the spinal osteoblast activity, suggesting ...
- Obesity 'triggers inflammation that damages the brain’on November 28, 2019 at 3:44 am
Obesity may trigger inflammation that damages the brain ... “In the future, we would like to repeat brain MRI in these adolescents after multi-professional treatment for weight loss to assess if the ...
- Inflammatory processes may play role in ALSon November 27, 2019 at 1:00 pm
In research led by investigators at Harvard-affiliated Massachusetts General Hospital (MGH) and published in Scientific Reports, treatment with an anti-inflammatory drug delayed the onset of disease ...
- BLOG: Dry eye treatment paradigm shiftson November 27, 2019 at 10:44 am
while stimulating production of the anti-inflammatory kind. An oral nutraceutical ... Correct diagnosis will guide the best course of treatment for the individual patient. For patients who do not get ...
- Prevent Suffering From Skin Inflammation This Winter By Avoiding This One Thingon November 27, 2019 at 4:30 am
how to prevent skin inflammation during winter Photo: 491013 - Pixabay This is why Dr. Felton ... Identifying the Difference Identifying the difference between eczema and dry skin is vital for its ...
- FDA-approved anti-inflammatory drug delays onset of ALS in miceon November 27, 2019 at 3:47 am
In research led by investigators at Massachusetts General Hospital (MGH) and published in Scientific Reports, treatment with an anti-inflammatory drug delayed the onset of disease in a mouse model of ...
via Bing News